微泡造影剂作为基因治疗中一种安全的载体，在超声辐照下能够有效的进行靶向性基因转染，成为当前肿瘤基因治疗领域的研究热点。目前，载基因靶向微泡存在微泡的靶向结合效率不高的缺陷，致使基因转染率不能达到理想的高度，成为制约该项技术进一步应用的瓶颈。本项目以改进微泡的靶向结合力为切入点，通过体外实验观察新型整合素αVβ3靶向微泡造影剂的靶向结合稳定性和安全性，通过体内实验观察肝癌靶向治疗的效果；同时运用基因转染、免疫组化、RT-PCR和Western blot等方法阐明整合素αVβ3靶向微泡介导KDR启动子驱动的CD/TK融合基因（KDRP-CD/TK）对肝癌细胞增殖能力和诱导凋亡的作用机制，为新型载基因微泡的肝癌靶向治疗提供实验依据和开拓新的思路。

As a safe gene therapy vector, microbubble contrast agent can be effective for targeted gene transfection under ultrasonic irradiation, and becomes the research hotspot in the current tumor gene therapy field. However, the gene transfection efficiency can not achieve the desired height because of the inefficient combining ability of the gene contained targeted microbubbles, and it becomes a bottleneck restricting the further application of this technology.Our current project aims to improve the targeted binding ability of the microbubbles as the starting point, observing the combination stability and security of the new integrin αVβ3 targeted microbubbles in vitro and the effect of targeted liver cancer therapy in vivo; At the same time, gene transfection, immunohistochemistry, RT-PCR and Western blot will be used to clarify the mechanism of KDR promoter-driven CD/TK fusion gene (KDRP-CD/TK) on the proliferationcapacity and induction of apoptosis mediated by integrin αVβ3 targeted microbubbles, providing the experimental basis and exploring new ideas for the targeted liver cancer therapy by novel gene carried microbubbles.